Acquired (Autoimmune) Hemolytic Anemia Market Size, Share, Analysis, Growth, 2032

Acquired (Autoimmune) Hemolytic Anemia Industry Prospective:

The global acquired (autoimmune) hemolytic anemia market size was evaluated at $752 million in 2023 and is slated to hit $1,016 million by the end of 2032 with a CAGR of nearly 7% between 2024 and 2032.

Request Free Sample

Acquired (Autoimmune) Hemolytic Anemia Market: Overview

Acquired (Autoimmune) Hemolytic Anemia is an autoimmune ailment characterized by the immune system that is attacked mistakenly & destroys the red blood corpuscles of human body. Reportedly, symptoms of the disease include fatigue, pale skin, weakness, and shortness of breath. Moreover, causes of acquired (autoimmune) hemolytic anemia include cancer, viral infections, an increase in the consumption of cephalosporins & penicillin, and autoimmune diseases.

Key Insights

• As per the analysis shared by our research analyst, the global acquired (autoimmune) hemolytic anemia market is projected to expand annually at the annual growth rate of around 7% over the forecast timespan (2024-2032)
• In terms of revenue, the global acquired (autoimmune) hemolytic anemia market size was evaluated at nearly $752 million in 2023 and is expected to reach $1,016 million by 2032.
• The global acquired (autoimmune) hemolytic anemia market is anticipated to grow rapidly over the forecast timeline owing to an increase in the incidences of autoimmune diseases along with a rising aging populace prone to these disorders.
• In terms of type, the warm autoimmune hemolytic anemia segment is slated to register the highest CAGR over the forecast period.
• Based on treatment, the corticosteroids segment is predicted to contribute majorly towards global industry surge in the ensuing years.
• On the basis of end-user, the hospitals segment is likely to maintain segmental domination in the forthcoming years.
• Region-wise, the Asia-Pacific acquired (autoimmune) hemolytic anemia industry is projected to register the fastest CAGR during the assessment timespan.

Acquired (Autoimmune) Hemolytic Anemia Market: Growth Factors

A surge in the incidence of autoimmune disorders can proliferate the growth of the global market

An increase in the cases of autoimmune diseases, along with a rising aging populace prone to this illness, will steer the growth of the global acquired (autoimmune) hemolytic anemia market. Apart from this, breakthroughs in the diagnostic techniques leading to early disease diagnosis will embellish the growth of the market globally.

In addition to this, an increase in healthcare spending in developed countries has propelled the demand for new treatment methods, thereby steering the global market trends. Surging patient awareness about acquired (autoimmune) hemolytic anemia and the key role played by patient advocacy groups in increasing awareness about patient care will amplify the growth of the market space in the years to come. Growing use of precision medicine in healthcare activities will help extend the growth graph of the global market in an upward direction.

Acquired (Autoimmune) Hemolytic Anemia Market: Restraints

Less options available in treating the disorder can scale down the industry growth

Availability of limited treatment alternatives and variations in severity & causes of the disease impacting its treatment can hamper the global acquired (autoimmune) hemolytic anemia industry expansion. Furthermore, regulatory challenges can pose a big threat to global industry expansion.

Acquired (Autoimmune) Hemolytic Anemia Market: Opportunities

Innovations in the treatment modes can open plethora of growth opportunities for the global market

Breakthroughs in medical treatments, along with the introduction of monoclonal antibodies, including rituximab, demonstrating high response in comparison to conventional treatments, will create new growth avenues for the global acquired (autoimmune) hemolytic anemia market.

Moreover, the uses of new kinds of medicines, such as FcRn inhibitors, including nipocalimab, as well as tyrosine kinase inhibitors, including fostamatinib, are being explored in various clinical experiments. Reportedly, these medicines are likely to provide new medical treatment ways for subjects with refractory acquired (autoimmune) hemolytic anemia, thereby steering the global market surge.

Acquired (Autoimmune) Hemolytic Anemia Market: Challenges

Escalating prices of disease identification & treatment can challenge the global industry surge over 2024- 2032

Huge costs of effectively monitoring & treating the disease can create hurdles in the growth path of the global acquired (autoimmune) hemolytic anemia industry. Furthermore, chances of disease relapse can hamper the global industry surge in the years ahead.

Acquired (Autoimmune) Hemolytic Anemia Market: Report Scope

Acquired (Autoimmune) Hemolytic Anemia Market: Segmentation

The global acquired (autoimmune) hemolytic anemia market is divided into type, treatment, end-user, and region.                 

In terms of type, the acquired (autoimmune) hemolytic anemia market across the globe is segmented into warm autoimmune hemolytic anemia and cold agglutinin disease segments. Apparently, the warm autoimmune hemolytic anemia segment, which garnered nearly half of the global market earnings in 2023, is projected to record the fastest CAGR in the next couple of years owing to the large-scale presence of warm antibodies in warm autoimmune hemolytic anemia, which attacks red blood corpuscles of human blood at normal temperature of the human body system. Moreover, warm autoimmune hemolytic anemia treatment requires effective diagnostic tools & treatment, thereby substantially driving the segmental surge.

Based on the treatment, the global acquired (autoimmune) hemolytic anemia industry is sectored into rituximab, corticosteroids, splenectomy, immunosuppressants, and blood transfusions segments. Furthermore, the corticosteroids segment, which dominated the global industry size in 2023, is likely to contribute substantively towards the global industry elevation over 2024-2032. This can be due to these medicines being the key treatment mode and also the first line of treating the disease due to their efficiency in suppressing the immune system of the human body and minimizing the destruction of red blood cells. 

On the basis of end-user, the global acquired (autoimmune) hemolytic anemia market is segregated into hospitals, homecare settings, and clinics segments. Moreover, the hospital segment, which dominated the segmental evolution in 2023, is expected to retain a segmental leadership position in the forecasting years owing to the need for intensive care, such as blood transfusions for patients and special diagnostic tests, which can only be availed in hospitals. Apart from this, hospitals have special modes of treatment, such as new immunosuppressive treatments and splenectomy. For the record, patient follow-up and routine check-ups of patient health are also performed in hospital settings.

Acquired (Autoimmune) Hemolytic Anemia Market: Regional Insights

North America is projected to maintain leading position in the global market over the projected timeframe

North America, which accounted for about 65% of the global acquired (autoimmune) hemolytic anemia market size in 2023, is expected to establish a leadership post in the global market during the forecasting years. In addition, the regional market elevation in the coming few years can be credited to the presence of developed healthcare infrastructure facilities and services. Moreover, a rise in healthcare spending and focus on developing new drug molecules will contribute significantly toward the regional market growth.

The Asia-Pacific acquired (autoimmune) hemolytic anemia industry is anticipated to register the highest CAGR in the expected timeframe. The swift elevation of the industry in Asia-Pacific can be ascribed to a surge in elderly people susceptible to autoimmune disorders.

Moreover, awareness about rare disorders and the availability of enhanced medical treatments preceded by a diagnosis of the disease in the early phase will prop up the market growth in the region. Reportedly, the presence of giant pharmaceutical & biotech firms in India and China is projected to change the overall landscape of the industry in the region.

Acquired (Autoimmune) Hemolytic Anemia Market: Competitive Space

The global acquired (autoimmune) hemolytic anemia market profiles key players such as:

• Nanjing IASO Biotherapeutics
• Incyte Corporation
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi SA
• Lupin Pharmaceuticals
• Viatris Inc.
• Bristol Myers Squibb
• Johnson & Johnson Services Inc.
• Rigel Pharmaceuticals Inc.
• Alpine Immune Sciences
• Cellics Therapeutics.

The global acquired (autoimmune) hemolytic anemia market is segmented as follows:

By Type

• Warm Autoimmune Hemolytic Anemia
• Cold Agglutinin Disease

By Treatment

• Rituximab
• Corticosteroids
• Splenectomy
• Immunosuppressants
• Blood Transfusions

By End-User

• Hospitals
• Homecare Settings
• Clinics

By Region

• North America

  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa